Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link. The Dow Jones Industrial Average ( ^DJI) is trading up 33 points (+0.2%) at 16,434 as of Wednesday, May 7, 2014, 10:35 a.m. ET. During this time, 86 million shares of the 30 Dow components have changed hands vs. an average daily trading volume of 396.2 million. The NYSE advances/declines ratio sits at 1,401 issues advancing vs. 1,476 declining with 184 unchanged.
EXCLUSIVE OFFER: Jim Cramer's Protégé, Dave Peltier, only buys Stocks Under $10 that he thinks could potentially double. See what he's trading today with a 14-day FREE pass.
Holding back the Dow today is Pfizer (NYSE: PFE), which is lagging the broader Dow index with a 19-cent decline (-0.7%) bringing the stock to $28.98. Volume for Pfizer currently sits at 11.3 million shares traded vs. an average daily trading volume of 29.1 million shares. Pfizer has a market cap of $191.55 billion and is part of the health care sector and drugs industry. Shares are down 3.9% year-to-date as of Tuesday's close. The stock's dividend yield sits at 3.5%. Pfizer Inc., a biopharmaceutical company, discovers, develops, manufactures, and sells healthcare products worldwide. Its product portfolio includes medicines and vaccines, as well as various consumer healthcare products. TheStreet Ratings rates Pfizer as a buy. The company's strengths can be seen in multiple areas, such as its impressive record of earnings per share growth, largely solid financial position with reasonable debt levels by most measures, reasonable valuation levels, good cash flow from operations and increase in stock price during the past year. We feel these strengths outweigh the fact that the company has had sub par growth in net income.